1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsEncourages exploratory and developmental research projects in the field of neurological disorders.
Get alerted about grants like this
Get emailed when new opportunities from “NIH NINDS” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profits, Small businesses, Individuals. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
R21 Exploratory/Developmental Research Grant is funded by NIH NINDS. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleOn September 3, 2026 — six days before the FY2027 Pioneer deadline — NIH posted forecast records for the entire FY2028 High-Risk, High-Reward program. The slate is nearly flat against FY2027, Transformative loses a slot, and the dollar figures quietly assume full negotiated indirect rates.
Read articleNOT-RM-26-004 asks the public for NIH-wide research challenges worth a 10-year, cross-institute program. There is no budget, no biosketch, no page limit, and no award. What there is: the five criteria every Common Fund investment has met since 2006, a new bullet about small-lab burden, and a fund whose FY 2026 request came in at $347.4 million — down 49.3 percent.
Read article